These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37745119)

  • 41. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial.
    Kosiborod MN; Jhund PS; Docherty KF; Diez M; Petrie MC; Verma S; Nicolau JC; Merkely B; Kitakaze M; DeMets DL; Inzucchi SE; Køber L; Martinez FA; Ponikowski P; Sabatine MS; Solomon SD; Bengtsson O; Lindholm D; Niklasson A; Sjöstrand M; Langkilde AM; McMurray JJV
    Circulation; 2020 Jan; 141(2):90-99. PubMed ID: 31736335
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Effects of Cholecalciferol Supplementation on FGF23 and α-Klotho in Hemodialysis Patients With Hypovitaminosis D: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Etemadi J; Samadifar M; Ghojazadeh M; Motavalli R; Oriyo R; Majidi T; Tayebi Khosroshahi H
    J Ren Nutr; 2022 May; 32(3):334-340. PubMed ID: 34294550
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial.
    Edelmann F; Wachter R; Schmidt AG; Kraigher-Krainer E; Colantonio C; Kamke W; Duvinage A; Stahrenberg R; Durstewitz K; Löffler M; Düngen HD; Tschöpe C; Herrmann-Lingen C; Halle M; Hasenfuss G; Gelbrich G; Pieske B;
    JAMA; 2013 Feb; 309(8):781-91. PubMed ID: 23443441
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF.
    Selvaraj S; Fu Z; Jones P; Kwee LC; Windsor SL; Ilkayeva O; Newgard CB; Margulies KB; Husain M; Inzucchi SE; McGuire DK; Pitt B; Scirica BM; Lanfear DE; Nassif ME; Javaheri A; Mentz RJ; Kosiborod MN; Shah SH;
    Circulation; 2022 Sep; 146(11):808-818. PubMed ID: 35603596
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ADDition of DAPAgliflozin, Sodium-Glucose Cotransporter-2 Inhibitor to Angiotensin Receptor Blocker-Neprilysin Inhibitors Non-Responders in Patient with Refractory Heart Failure with Reduced Ejection Fraction (ADD DAPA trial).
    Jariwala P; Jadhav K; Punjani A; Boorugu H; Mari AR
    Indian Heart J; 2021; 73(5):605-611. PubMed ID: 34627577
    [TBL] [Abstract][Full Text] [Related]  

  • 46. FGF23 and Klotho in relation to markers of endothelial dysfunction in kidney transplant recipients.
    Malyszko J; Koc-Zorawska E; Matuszkiewicz-Rowinska J; Malyszko J
    Transplant Proc; 2014 Oct; 46(8):2647-50. PubMed ID: 25380886
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fibroblast Growth Factor-23 and Heart Failure With Reduced Versus Preserved Ejection Fraction: MESA.
    Almahmoud MF; Soliman EZ; Bertoni AG; Kestenbaum B; Katz R; Lima JAC; Ouyang P; Miller PE; Michos ED; Herrington DM
    J Am Heart Assoc; 2018 Sep; 7(18):e008334. PubMed ID: 30371180
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction.
    Berg DD; Jhund PS; Docherty KF; Murphy SA; Verma S; Inzucchi SE; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Bengtsson O; Ponikowski P; Sjöstrand M; Solomon SD; McMurray JJV; Sabatine MS
    JAMA Cardiol; 2021 May; 6(5):499-507. PubMed ID: 33595593
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
    Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
    Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Alpha Klotho and Fibroblast Growth Factor-23 Among Alcoholics.
    Quintero-Platt G; González-Reimers E; Rodríguez-Gaspar M; Martín-González C; Pérez-Hernández O; Romero-Acevedo L; Espelosín-Ortega E; Vega-Prieto MJ; Santolaria-Fernández F
    Alcohol Alcohol; 2017 Sep; 52(5):542-549. PubMed ID: 28651327
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
    Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR;
    JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Decreased concentration of klotho and increased concentration of FGF23 in the cerebrospinal fluid of patients with narcolepsy.
    da Paz Oliveira G; Elias RM; Peres Fernandes GB; Moyses R; Tufik S; Bichuetti DB; Coelho FMS
    Sleep Med; 2021 Feb; 78():57-62. PubMed ID: 33385780
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial.
    Solomon SD; Vaduganathan M; Claggett BL; de Boer RA; DeMets D; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Belohlavek J; Chiang CE; Willem Borleffs CJ; Comin-Colet J; Dobreanu D; Drozdz J; Fang JC; Alcocer Gamba MA; Al Habeeb W; Han Y; Cabrera Honorio JW; Janssens SP; Katova T; Kitakaze M; Merkely B; O'Meara E; Kerr Saraiva JF; Tereschenko SN; Thierer J; Vardeny O; Verma S; Vinh PN; Wilderäng U; Zaozerska N; Lindholm D; Petersson M; McMurray JJV
    JACC Heart Fail; 2022 Mar; 10(3):184-197. PubMed ID: 35241246
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant-level pooled analysis from the DAPA-HF and DELIVER trials.
    Bhatt AS; Kosiborod MN; Vaduganathan M; Claggett BL; Miao ZM; Kulac IJ; Lam CSP; Hernandez AF; Martinez F; Inzucchi SE; Shah SJ; de Boer RA; Jhund PS; Desai AS; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
    Eur J Heart Fail; 2023 Jul; 25(7):981-988. PubMed ID: 37211977
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF.
    Docherty KF; Jhund PS; Anand I; Bengtsson O; Böhm M; de Boer RA; DeMets DL; Desai AS; Drozdz J; Howlett J; Inzucchi SE; Johanson P; Katova T; Køber L; Kosiborod MN; Langkilde AM; Lindholm D; Martinez FA; Merkely B; Nicolau JC; O'Meara E; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Tereshchenko S; Verma S; McMurray JJV
    Circulation; 2020 Oct; 142(17):1623-1632. PubMed ID: 32883108
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association between circulating fibroblast growth factor 23, α-Klotho, and the left ventricular ejection fraction and left ventricular mass in cardiology inpatients.
    Shibata K; Fujita S; Morita H; Okamoto Y; Sohmiya K; Hoshiga M; Ishizaka N
    PLoS One; 2013; 8(9):e73184. PubMed ID: 24039882
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF.
    Inzucchi SE; Docherty KF; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; Sabatine MS; Solomon SD; Verma S; Bělohlávek J; Böhm M; Chiang CE; de Boer RA; Diez M; Dukát A; Ljungman CEA; Bengtsson O; Langkilde AM; Sjöstrand M; Jhund PS; McMurray JJV;
    Diabetes Care; 2021 Feb; 44(2):586-594. PubMed ID: 33355302
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF.
    Adamson C; Cowan LM; de Boer RA; Diez M; Drożdż J; Dukát A; Inzucchi SE; Køber L; Kosiborod MN; Ljungman CEA; Martinez FA; Ponikowski P; Sabatine MS; Lindholm D; Bengtsson O; Boulton DW; Greasley PJ; Langkilde AM; Sjöstrand M; Solomon SD; McMurray JJV; Jhund PS
    Eur J Heart Fail; 2022 Oct; 24(10):1856-1868. PubMed ID: 36054568
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial.
    Komajda M; Isnard R; Cohen-Solal A; Metra M; Pieske B; Ponikowski P; Voors AA; Dominjon F; Henon-Goburdhun C; Pannaux M; Böhm M;
    Eur J Heart Fail; 2017 Nov; 19(11):1495-1503. PubMed ID: 28462519
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Role of the morphogenetic proteins FGF-23 and Klotho and the glycoprotein sclerostin in the assessment of the risk of cardiovascular diseases and the prognosis of chronic kidney disease].
    Milovanova LY; Milovanov YS; Kudryavtseva DV; Markina MM; Milovanova SY; Kozlovskaya LV; Lebedeva MV; Beketov VD; Moiseev SV; Mukhin NA; Fomin VV; Svistunov AA
    Ter Arkh; 2015; 87(6):10-16. PubMed ID: 26281189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.